Long-term Dupilumab Therapy in a Pediatric Patient with Netherton Syndrome: A Case Report and Review of the Literature
Open Access
- 1 May 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Asian Journal of Pediatric Dermatology
- Vol. 2 (2) , 63-67
Abstract
Netherton syndrome (NS) is an inherited ichthyosis without targeted therapies, and current treatment remains largely symptomatic. Herein, we report the case of a 6-year-old patient with NS successfully managed with dupilumab for 3 years. The literature regarding dupilumab treatment in this patient population is summarized, and the potential role of dupilumab in altering the pathogenesis of NS is discussed.Keywords
This publication has 23 references indexed in Scilit:
- Emerging Role of the IL-36/IL-36R Axis in Multiple Inflammatory Skin DiseasesJournal of Investigative Dermatology, 2024
- Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responsesJournal of Allergy and Clinical Immunology, 2022
- Successful treatment of Netherton syndrome with dupilumab: A case report and review of the literatureThe Journal of Dermatology, 2021
- Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndromeJournal of Dermatological Science, 2021
- Secukinumab Therapy for Netherton SyndromeJAMA Dermatology, 2020
- Treatment of Netherton Syndrome With DupilumabJAMA Dermatology, 2020
- Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signatureJournal of Allergy and Clinical Immunology, 2019
- Netherton syndrome: skin inflammation and allergy by loss of protease inhibitionCell and tissue research, 2013
- Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndromeNature Genetics, 2000
- A Unique Case of Trichorrhexis Nodosa—"Bamboo Hairs"Archives of Dermatology, 1958